Document text
Principal Investigator: NASSER Khaled ALTORKI
Organization: WEILL MEDICAL COLL OF CORNELL UNIV
Fiscal Year: 2022
Award: $1,180,595
Funding agency: National Cancer Institute
Overall Component: Project Summary/Abstract
The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and
validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer
risk. The PI is Dr. Lipkin, an established leader in Cancer Prevention who has made several important, clinically
translated contributions to the field. Project 1 will develop and validate an LNP RNA immunoprevention vaccine
for Lynch syndrome, a genetic cancer predisposition syndrome with highly immunogenic recurrent neoantigens
shared among cancers from different patients. Project 2 will develop and validate an LNP RNA immune
interception vaccine for patients with lung non-solid nodule (NSN) pre-malignant neoplasms, a lung
adenocarcinoma precursor lesion. To achieve these goals, we will use state-of-the-art technologies, including
LNP RNA vaccine formulation, computational genomic tumor immunology, spatial genomics and
immunopeptidomics. To ensure CRI's scientific rigor and excellence, we have assembled a scientifically
outstanding CRI External Advisory Board (EAB), which includes 2021 Lasker Award winner Drew Weissman
(Penn) for his work on LNP RNA COVID19 vaccines. Overall, the CAP-IT CRI will develop state-of-the-art LNP RNA
immunoprevention and immune interception vaccines and provide a technologically powerful platform to
jumpstart additional CAP-IT CRI LNP RNA vaccine projects. We anticipate that CAP-IT CRI will propel both
Lynch syndrome and lung NSN vaccines to NCI PREVENT and CP-NET clinical trials within the next 5 years
and FDA approval/clinical translation within ten years.
Terms: <2019-nCoV vaccine><Acute Poliomyelitis><Antigens><Architecture><Autologous><Award><Biotech><Biotechnology><COVID-19><COVID-19 vaccine><COVID19><COVID19 vaccine><CV-19><CV19><Cancer Burden><Cancers><Cessation of life><Clinic><Clinical><Clinical Trials><Clonal Evolution><Communicable Diseases><Computer Analysis><Data><Data Bases><Databases><Death><Division of Cancer Prevention><Engineering / Architecture><Ensure><Familial Nonpolyposis Colon Cancer><Genomics><Goals><HIPAA><HNPCC><Health Insurance Portability and Accountability Act><Hereditary><Hereditary Colo-rectal Endometrial Cancer Syndrome><Hereditary Colorectal Endometrial Cancer Syndrome><Hereditary Defective Mismatch Repair Syndrome><Hereditary Non-Polyposis Colon Cancer><Hereditary Nonpolyposis Colo-rectal Cancer><Hereditary Nonpolyposis Colo-rectal Neoplasms><Hereditary Nonpolyposis Colon Cancer><Hereditary Nonpolyposis Colorectal Cancer><Hereditary Nonpolyposis Colorectal Neoplasms><History><I-RNA><Immune><Immune Surveillance><Immunes><Immunologic Surveillance><Immunologic Surveillances><Immunological Surveillance><Immunological Surveillances><Immunoprevention><Immunosurveillance><In Vitro><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inherited><Intercept><Kennedy Kassebaum Act><LS/HNPCC><Lesion><Lung><Lung Adenocarcinoma><Lung Respiratory System><Lynch Syndrome><Malignant Neoplasms><Malignant Tumor><Medical><Meningococcus><N meningitidis><N. meningitidis><National Cancer Burden><Neisseria meningitidis><Nodule><Non-Polyadenylated RNA><PL 104-191><PL104-191><Patients><Polio><Poliomyelitis><Predisposition><Premalignant Neoplasm><Preventative strategy><Prevention><Prevention strategy><Preventive strategy><Primary Cancer Prevention><Public Law 104-191><RNA><RNA Gene Products><RNA immunization><RNA vaccination><RNA vaccine><RNA-based vaccine><Recording of previous events><Recurrence><Recurrent><Research><Resource Sharing><Ribonucleic Acid><Role><SARS-CoV-2 vaccine><SARS-CoV2 vaccine><SARS-coronavirus-2 vaccine><Science><Services><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Smoker><Sum><Susceptibility><Syndrome><T-Cells><T-Lymphocyte><Technology><Translating><Tumor Antigens><Tumor-Associated Antigen><United States Health Insurance Portability and Accountability Act><Vaccines><Validation><Work><anti-cancer immunotherapy><anticancer immunotherapy><biobank><biorepository><cancer antigens><cancer cell genome><cancer genetics><cancer genome><cancer genomics><cancer immunology><cancer immunotherapy><cancer predisposition><cancer prevention><cancer risk><clinical translation><computational analyses><computational analysis><computer analyses><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 vaccine><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus infectious disease-19><cytotoxicity test><data base><discover vaccines><efficacy testing><experience><flexibility><flexible><global gene expression><global transcription profile><hereditary non-polyposis colo-rectal cancer><hereditary non-polyposis colorectal cancer><immune RNA><immune-based cancer therapies><immunogen><immunogenic><immunogenicity><immunotherapy for cancer><immunotherapy of cancer><in vivo><in vivo Model><individualized prevention><innovate><innovation><innovative><lipid based nanoparticle><lipid nanoparticle><mRNA immunization><mRNA vaccination><mRNA vaccine><mRNA-based vaccine><malignancy><mouse model><murine model><neo-antigen><neo-epitopes><neoantigens><neoepitopes><neoplasm immunology><neoplasm/cancer><oncogenomics><patient population><personalized prevention><pre-clinical><precision prevention><preclinical><programs><pulmonary><social role><success><thymus derived lymphocyte><transcriptome><tumor><tumor genome><tumor immunology><tumor-specific antigen><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine discovery><vaccine for novel coronavirus><vaccine formulation>